当前位置:
首页
>
产品中心 >
Recombinant_antibodies >
Antibodiesinc/Pan-Neurofascin (extracellular)/75-172/1 Ea
Antibodiesinc/Pan-Neurofascin (extracellular)/75-172/1 Ea
商品编号:
75-172
市场价:
¥0.00
美元价:
0.00
产品分类:
重组抗体
公司分类:
Recombinant_antibodies
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
Lipid raft fractions isolated from adult rat brain. Target identified as Neurofascin by:
- binding to NF-186-tranfected COS cells
- recognition of NF155 and NF186 but not other highly related L1 CAMs like NrCAM
- immunoprecipitation of NF155 and NF186 and confirmation by mass spectrometry
- loss of immunostaining against NF186-shRNA knockdown samples
Rat: amino acids 25-1110 (extracellular domain common to NF155 and NF186)
Mouse: 98% identity (1074/1086 amino acids identical)
Human: 79% identity (955/1195 amino acids identical)
This NeuroMab antibody is considered "Restricted" and is therefore not available for commercial re-distribution on a for-profit basis.
- binding to NF-186-tranfected COS cells
- recognition of NF155 and NF186 but not other highly related L1 CAMs like NrCAM
- immunoprecipitation of NF155 and NF186 and confirmation by mass spectrometry
- loss of immunostaining against NF186-shRNA knockdown samples
Rat: amino acids 25-1110 (extracellular domain common to NF155 and NF186)
Mouse: 98% identity (1074/1086 amino acids identical)
Human: 79% identity (955/1195 amino acids identical)
This NeuroMab antibody is considered "Restricted" and is therefore not available for commercial re-distribution on a for-profit basis.
Specifications:
Target |
Pan-Neurofascin (extracellular) | |
Applications |
Immunoblot (IB) Immunohistochemistry (IHC) Immunoprecipitation (IP) |
|
Clone |
A12/18 | |
IgG Isotype |
IgG2a | |
Species Reactivity |
Rat (R) | |
Validation |
Br-IB Br-IHC T |
|
Type |
Purified | |
Format |
100 ul | |
Cross Reactivity |
None Reported | |
Expected Banding Pattern |
155, 186 kDa | |
Host |
Mouse (M) | |
Label |
Unlabeled | |
Antibody Type |
Monoclonal | |
Commercial Price |
450 | |
Non-Profit Price |
200 | |
Distributor Price |
Per Contract(QUOTE) | |
ABID |
RRID:AB_2282826 | |
品牌介绍
当抗体公司(Antibodies Incorporated)在1962年开业时,与抗体相关的研究才刚刚开始。创始人Jim Hillman拥有博士学位。从药理学明尼苏达大学,来到加州大学戴维斯分校在免疫化学完整的博士后工作,在工作期间,他学习了加州理工学院(加州理工学院)根据丹·坎贝尔,领域的先驱。吉姆带来了他的妻子,公司的共同创始人卡罗尔(Carol)和两个孩子,以及使用基于抗体的化学疗法寻找治疗癌症的能量和想法。具体地说,吉姆认为,如果他能够识别并分离出可能具有抗原性的肿瘤部位(一个焦点是淋巴肉瘤),则可能有可能进行有效的基于抗体的治疗。吉姆寻找这种治疗方法的梦想推动了他的工作多年。